Skip to main contentAI and Advanced
/
GUJTHEM · NSEMarket ticker unavailable · configure an authorised index feed
GU
NSE · Equity shares · Biotechnology & Drugs-13.25 · -3.13%
Gujarat Themis Biosyn GUJTHEM
NSE:INR 410.25
BSE:INR 361
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for GUJTHEM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 423.5
Day rangeINR 401.95 — INR 427.95
52-week rangeINR 225.05 — INR 479
Volume3.93 L
Market cap3,932.54
P/E53.01
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)165.82
Net Income (INR Cr)46.68
Rev Growth (5 Year %)12.86
EPS Growth (5 Year %)9.09
P/E Ratio53.01
Book Value26.4
EPS4.28
Price/BV15.54Computed
Research path: Interpret Gujarat Themis Biosyn's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GUJTHEMGujarat Themis Biosyn1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 503.43 | 301.31 | 221.11 |
| Cash Equivalents | 6.09 | 10.05 | 6.39 |
| Other Liabilities Total | 1.21 | 0.77 | 0.69 |
| Long Term Debt | 128.06 | 28.65 | 0 |
| Common Stock Total | 10.9 | 10.9 | 7.26 |
| Other Current Assets Total | 6.02 | 2.85 | 0.42 |
| Total Assets | 503.43 | 301.31 | 221.11 |
| Current Portof LT Debt/Capital Leases | 1.3 | 0.83 | 1.54 |
| Total Equity | 287.77 | 248.38 | 201.38 |
| Long Term Investments | 0.93 | 0.94 | 31.04 |
| Retained Earnings(Accumulated Deficit) | 276.87 | 237.49 | 191.95 |
| Total Common Shares Outstanding | 10.9 | 10.9 | 10.9 |
| Tangible Book Valueper Share Common Eq | 26.4 | 22.78 | 18.48 |
| Total Liabilities | 215.66 | 52.93 | 19.74 |
| Total Debt | 161.81 | 30.47 | 2.77 |
| Short Term Investments | 0.33 | 0 | 8.11 |
| Cashand Short Term Investments | 6.42 | 12.03 | 15.35 |
| Total Receivables Net | 60.92 | 31.89 | 28.11 |
| Notes Payable/Short Term Debt | 31.8 | 0 | 0 |
| Deferred Income Tax | 6.59 | 1.96 | 1.66 |
| Accounts Receivable-Trade Net | 60.92 | 31.45 | 27.59 |
| Property/Plant/Equipment Total-Net | 410.02 | 225.54 | 129.24 |
| Total Current Liabilities | 79.15 | 20.56 | 16.16 |
| Total Inventory | 15.42 | 5.05 | 3.33 |
| Accounts Payable | 36.65 | 14.65 | 9.91 |
| Other Currentliabilities Total | 9.4 | 5.08 | 4.71 |
| Total Long Term Debt | 128.72 | 29.64 | 1.22 |
| Intangibles Net | 0.1 | 0.16 | Not available |
| Other Long Term Assets Total | 2.85 | 0.66 | 0.87 |
| Note Receivable-Long Term | 0.75 | 22.04 | 12.41 |
| Total Current Assets | 88.78 | 51.97 | 47.56 |
| Capital Lease Obligations | 0.65 | 0.99 | 1.22 |
| Accumulated Depreciation Total | Not available | -18 | -13.19 |
| Other Equity Total | Not available | 0 | 0 |
| Prepaid Expenses | Not available | 0.16 | 0.36 |
| Additional Paid-In Capital | Not available | 0 | 2.16 |
| Cash | Not available | 1.98 | 0.85 |
| Property/Plant/Equipment Total-Gross | Not available | 59.13 | 51.21 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %101.85
Margins
Operating Margin 12m37.76
Operating Margin 5y Avg43.83
Net Profit Margin 12m28.15
Net Profit Margin 5y34.15
Yield
Dividend Yield %0.19
Valuation
Price to Sale Ratio23.72
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk57.31
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
Shareholding
Ownership
- Promoter
- 70.86%
- FII
- 1.76%
- MF
- 1.16%
- Other
- 26.22%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Gujarat Themis Biosyn Ltd Hits Intraday Low Amid Price Pressure - Markets MojoMarket news · 5 Jun 2026, 7:13 am
Gujarat Themis Biosyn Ltd Hits Intraday Low Amid Price Pressure Markets Mojo
Gujarat Themis Biosyn board to meet on June 6 to consider fund raising - scanx.tradeMarket news · 3 Jun 2026, 6:34 pm
Gujarat Themis Biosyn board to meet on June 6 to consider fund raising scanx.trade
Gujarat Themis Biosyn Ltd Downgraded to Sell Amid Technical and Financial Concerns - Markets MojoMarket news · 3 Jun 2026, 2:47 pm
Gujarat Themis Biosyn Ltd Downgraded to Sell Amid Technical and Financial Concerns Markets Mojo
Gujarat Themis Biosyn’s Rs 3,000 crore bet: Can it build a global pharma platform? - The Indian ExpressMarket news · 3 Jun 2026, 6:30 am
Gujarat Themis Biosyn’s Rs 3,000 crore bet: Can it build a global pharma platform? The Indian Express
Gujarat Themis Biosyn Ltd Faces Technical Momentum Shift Amid Mixed Indicator Signals - Markets MojoMarket news · 2 Jun 2026, 8:32 am
Gujarat Themis Biosyn Ltd Faces Technical Momentum Shift Amid Mixed Indicator Signals Markets Mojo
Gujarat Themis Biosyn's (NSE:GUJTHEM) Anemic Earnings Might Be Worse Than You Think - simplywall.stMarket news · 1 Jun 2026, 1:46 pm
Gujarat Themis Biosyn's (NSE:GUJTHEM) Anemic Earnings Might Be Worse Than You Think simplywall.st
Corporate actions
Events
- annual General MeetingEGM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board Meetings(Cancelled )
- annual General MeetingPOM
- board MeetingsTo consider other business matters.
- dividendRs.0.6700 per share(67%)Final Dividend
- board MeetingsTo consider other business matters.
Rusaka Markets Community
Discussion and sentiment for Gujarat Themis Biosyn
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through pharmaceuticals segment. Its product portfolio comprises Rifamycin-S and Lovastatin. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy).
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- GUJTHEM
- BSE Code
- 506879
Questions
Stock FAQ
What is the symbol and ISIN of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has the symbol GUJTHEM and ISIN - INE942C01045.
What is the current price of Gujarat Themis Biosyn?
Gujarat Themis Biosyn is currently trading at INR 410.25.
What are the year high and year low of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a year high of INR 479.00 and a year low of INR 225.05.
What is the market capitalization of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a market capitalization of INR 3,932.54 crore.
What is the P/E ratio of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a P/E ratio of 53.01.
What is the dividend yield of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a dividend yield of 0.19%.
How is the financial performance of Gujarat Themis Biosyn based on revenue, net income, and EPS?
Gujarat Themis Biosyn has revenue of INR 165.82 crore, net income of INR 46.68 crore, and EPS of INR 4.28.
What is the book value of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a book value of INR 26.40.
What is the debt-to-equity ratio of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Gujarat Themis Biosyn?
Gujarat Themis Biosyn has a price-to-book ratio of 15.54 and a price-to-sales ratio of 23.72.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.